Naurex leads VC funding surge with $80 Series C

December began with what looks like an end-of-year venture capital dealmaking rush, including an $80m Series C round to fund Naurex's drug candidates for depression and central nervous system (CNS) disorders plus four other sizeable US biotechnology deals.